Loading...
Loading...
SUPN| Name | Value |
|---|---|
| Revenues | 175.7M |
| Cost of Revenue | 37.7M |
| Gross Profit | 138.0M |
| Operating Expense | 98.8M |
| Operating I/L | 40.8M |
| Other Income/Expense | 4.1M |
| Interest Income | 0.0M |
| Pretax | 44.9M |
| Income Tax Expense | 6.4M |
| Net Income/Loss | 38.5M |
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's revenue is generated through the sale of its commercial products, including Trokendi XR for epilepsy and migraine, Oxtellar XR for epilepsy, Qelbree for ADHD, APOKYN for Parkinson's Disease, XADAGO for PD off episodes, MYOBLOC for cervical dystonia and sialorrhea, GOCOVRI for PD dyskinesia, and Osmolex ER for Parkinson's disease and drug-induced extrapyramidal reaction. Additionally, the company has several product candidates in various stages of development for treating CNS disorders.
